BeiGene Raises New Funds For Oncology Pipeline
This article was originally published in PharmAsia News
Executive Summary
Chinese bioventure BeiGene has raised additional funding from existing and new investors, providing it with new resources to take forward through early clinical trials several molecules for cancer.
You may also be interested in...
Merck Invests In China Oncology Start-up BeiGene
Merck & Co. affiliate MSD has invested an undisclosed amount of debt and equity financing in the Beijing-based start-up biotech BeiGene, Ltd., BeiGene announced May 2
Japan Enhertu Nod Another Boost For Daiichi's Oncology Hopes
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
GTS Alliance Gives Mochida A Cell Therapy Buy-In
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
Need a specific report? 1000+ reports available
Buy Reports